One site for Breaking News, Politics, Sports, Entertainment & more!

Newz Chooze

Biopharmaceutical company Mersana Therapeutics Inc. said Friday that it will discontinue development of its XMT-1522 cancer treatment, following a strategic evaluation by the company. The stock is currently halted for news. Instead, the company will focus its resources on advancing XMT-1536. XMT-1522 was being developed with its partner, Takeda Pharmaceutical Co. Ltd. . "We have made the difficult decision to terminate the further development of XMT-1522 despite a favorable emerging profile of efficacy and tolerability due to the competitive environment for HER2-targeted therapies," said Mersana Chief Executive Anna Protopapas. The company said it plans to report phase 1 trial dose escalation data in the first half of 2019. The stock has plunged 56% over the past three months, while the iShares Nasdaq Biotechnology ETF has lost 17% and the S&P 500 has shed 16%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.